Venture Kick

Clee Medical believes the rapid growth of neurotech is constrained by inefficiencies in surgical tools and techniques.

Lighthouse Tech specializes in designing smart eyewear frames aimed at individuals with vision impairment, blindness, and spatial perceptual disorders. Their innovative product detects obstacles above the waist and alerts users through soft haptic vibrations. The eyewear is crafted to resemble conventional frames or sunglasses, ensuring that users do not compromise on style while benefiting from enhanced safety and mobility. By combining functionality with fashion, Lighthouse Tech promotes independent outdoor navigation, ultimately fostering a greater sense of self-sufficiency and well-being for its customers.

ValTech Lifesciences is a medtech startup promoting cardiovascular health through its proprietary heart valve characteristics that improve the performance of mechanical and biological prostheses.

dEEGtal’s use of AI to expedite epilepsy diagnosis could make a significant difference in patient care, by analyzing EEG data quickly, it might help identify patterns or anomalies that could be missed by human reviewers alone.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

Suri BioTech is a biotechnology company focused on developing health-promoting bacterial strains aimed at alleviating bloating and intestinal discomfort. The company specializes in creating science-based probiotics, particularly for infant health, utilizing proprietary strains that reduce hydrogen gas production by intestinal microorganisms. This innovative approach has potential applications in various functional gastrointestinal disorders, including infant colic and lactose intolerance. By leveraging its biotech platform, Suri BioTech seeks to provide effective solutions for individuals suffering from gastrointestinal issues.

Sensemodi develops an AI-powered smart wearable device that assesses joint health, particularly focusing on the knee and other joints. By utilizing a combination of thermal, acoustic, and kinematic data, the device provides a quick evaluation of joint conditions. This innovative technology aims to prevent disabilities and reduce the socioeconomic burden associated with musculoskeletal disorders. The wearable allows users to conveniently monitor their joint health, facilitating access to improved healthcare treatments and promoting proactive management of joint-related issues.

Oncobit is focused on enhancing personalized cancer care through the development of precise and highly sensitive diagnostic and monitoring tests. The company combines technical expertise with proprietary software and engages in close clinical collaborations, initially concentrating on melanoma while maintaining the potential to expand its solutions to other cancer types. Oncobit's innovative approach aims to improve patient outcomes by providing comprehensive and sensitive tests that enable clinics to offer tailored therapies and diagnostics, ensuring that cancer monitoring keeps pace with advancements in treatment methodologies.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the nervous system. Neural implants are medical devices made of electrodes that can record or stimulate the brain, spinal cord, or peripheral nerves to monitor or treat patients suffering from neurological disorders. However, current clinical devices are too stiff compared to the soft tissues of the body, which limits benefits for patients. At Neurosoft Bioelectronics, we have developed a new generation of soft and conformable implantable electrodes that seamlessly interface with the nervous tissues and can improve clinical outcomes for patients.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

Bota Systems AG, based in Zurich, Switzerland, specializes in the development and manufacture of advanced sensors for robotic applications. Incorporated in 2020, the company produces a range of products including force torque sensors, load cells, and robotic grippers designed to enhance the functionality of robotic arms, exoskeletons, prosthetic devices, and surgical platforms. Bota Systems' offerings include the Rokubi and SensONE force torque sensors, which facilitate safe and efficient interactions between robots and their environments. By providing high-quality and cost-effective components, the company aims to meet the growing demand for automation technology, enabling clients to implement integrated robotic solutions that streamline processes and improve productivity.

No-Touch Robotics specializes in the development and manufacturing of contactless robotic manipulators and grippers designed to handle small and fragile objects without mechanical contact. Their innovative solutions utilize electromechanical transducers and proprietary control software to manipulate, move, and monitor objects, ensuring there is no damage or contamination. This technology is particularly beneficial for automating processes that traditionally required manual handling, such as laboratory tasks in microscopy and 3D printing. By providing a safe and efficient means of object manipulation, No-Touch Robotics aims to enhance automation in various industries, addressing the needs of clients who require precision and care in handling delicate items.

LifeMatrix specializes in the development of biomimetic implants and bio-engineering technology aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company creates human cell-derived, off-the-shelf tissue-engineered implants that transform into living tissue after implantation, allowing them to grow and regenerate alongside the patient. This innovative technology addresses the limitations of traditional implants and is designed to enhance patient recovery. LifeMatrix's award-winning solutions are founded on over 20 years of extensive research, supported by multiple national and international grants, and validated through more than 100 peer-reviewed publications. Preclinical studies have demonstrated the safety and efficacy of these implants, paving the way for their clinical application.

Helvitek Labs, founded in 2019 and based in Lausanne, specializes in developing advanced anti-pollution face masks. The company was established by Théo-Tim Denisart, a graduate of the Swiss Federal Institute of Technology in Lausanne, and Roberto Costa, a former marketing director at Swatch, motivated by their experiences with severe air pollution in China. Helvitek Labs focuses on integrating artificial intelligence with innovative filtering and sealing technologies to improve mask comfort and effectiveness, particularly for health professionals who endure prolonged use of traditional respirators. Their efforts have garnered significant support, including recognition at the Start Lausanne contest and grants from the EPFL and the Vaud Foundation for Technological Innovation, which enabled the firm to establish itself within the EPFL Innovation Park and build a dedicated team. Officially incorporated as a public limited company in March 2020, Helvitek Labs aims to address the challenges associated with air quality and mask usage.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

epyMetrics AG is a Swiss health analytics company that specializes in developing diagnostic wearable solutions aimed at monitoring the body's heat balance. Incorporated in 2019 and based in Zurich, the company offers a comprehensive platform that enables users to continuously and non-invasively track their thermoregulation. Its technology detects early signs of heat stress, facilitating the prevention of heat-related accidents. The wearable device captures vital signs, including sweat rate and total sweat loss, providing crucial data that allows industries to identify the risk of heat exhaustion. By offering personalized safety benchmarks, epyMetrics aims to enhance safety protocols and reduce costs associated with heat-related incidents.

EarlySight start-up company is founded in order to accelerate the development and to bring the technology to clinics.

SurgeonsLab, founded in 2020 and based in Bern, Switzerland, specializes in developing patient-specific training models for surgical procedures and the validation of new medical devices. The company focuses on microsurgical treatment planning and strategy, providing tools that enhance the training experience for medical professionals. By utilizing advanced technology, SurgeonsLab's products facilitate testing and planning for surgical interventions, significantly improving patient safety and outcomes. The company's innovative approach offers an alternative to traditional human and animal models, thereby enhancing the learning curve for medical trainees.

Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the nervous system. Neural implants are medical devices made of electrodes that can record or stimulate the brain, spinal cord, or peripheral nerves to monitor or treat patients suffering from neurological disorders. However, current clinical devices are too stiff compared to the soft tissues of the body, which limits benefits for patients. At Neurosoft Bioelectronics, we have developed a new generation of soft and conformable implantable electrodes that seamlessly interface with the nervous tissues and can improve clinical outcomes for patients.

Testmate Health is a medtech startup and an award-winning spin-off of the University of Geneva, focused on developing innovative healthcare solutions. The company has created a smartphone-compatible test kit that can diagnose diseases with identifiable DNA or RNA sequences, providing results directly at home in just minutes. Its first product is a rapid urine self-test for the four most common sexually transmitted diseases, addressing the urgent need for timely diagnosis, as one million new STDs are diagnosed daily. Traditional testing often requires lab work and can take up to seven days for results. Testmate Health's all-in-one kit is designed for ease of use, allowing users to obtain immediate results that can be scanned by a smartphone for quick access to treatment if necessary. The company is also working on additional test kits for other diseases, aiming to empower individuals to manage their health conveniently from home.

Bota Systems AG, based in Zurich, Switzerland, specializes in the development and manufacture of advanced sensors for robotic applications. Incorporated in 2020, the company produces a range of products including force torque sensors, load cells, and robotic grippers designed to enhance the functionality of robotic arms, exoskeletons, prosthetic devices, and surgical platforms. Bota Systems' offerings include the Rokubi and SensONE force torque sensors, which facilitate safe and efficient interactions between robots and their environments. By providing high-quality and cost-effective components, the company aims to meet the growing demand for automation technology, enabling clients to implement integrated robotic solutions that streamline processes and improve productivity.

KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.

Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

Artiria Medical SA develops innovative micro-actuated devices aimed at treating vascular diseases, particularly in the brain. Founded in 2019 and based in Lausanne, Switzerland, the company focuses on enhancing the precision and control of surgical procedures involving catheters and guidewires. Its technology facilitates micromotion within brain arteries, thereby improving navigation during stroke treatments. By enabling surgeons to perform these complex procedures with greater accuracy, Artiria Medical contributes to better patient outcomes and the potential to save lives.

Auxivo AG is a company based in Zürich, Switzerland, specializing in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing strain and fatigue, Auxivo's exoskeletons enhance worker safety and overall well-being, helping to prevent injuries and improve productivity in the workplace. The company's focus on creating accessible and effective solutions aims to ensure that workers can perform their duties with greater ease and security.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.

Artiria Medical SA develops innovative micro-actuated devices aimed at treating vascular diseases, particularly in the brain. Founded in 2019 and based in Lausanne, Switzerland, the company focuses on enhancing the precision and control of surgical procedures involving catheters and guidewires. Its technology facilitates micromotion within brain arteries, thereby improving navigation during stroke treatments. By enabling surgeons to perform these complex procedures with greater accuracy, Artiria Medical contributes to better patient outcomes and the potential to save lives.

Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.

B-rayZ is a spin-off from the University Hospital Zurich, focused on enhancing radiology through advanced technology. The team comprises experienced radiologists, data scientists, and physicians with over 15 years of expertise in medical imaging. B-rayZ develops artificial intelligence-based software that aids radiologists in mammography by offering real-time assessments of image quality and breast density. This innovative software enables accurate and standardized evaluations of medical imaging data, thereby improving breast cancer detectability. By providing intelligent tools, B-rayZ supports radiologists in enhancing their diagnostic capabilities while also contributing to reduced healthcare costs.

SwissSource Instruments specializes in the development and sale of ionization sources tailored for mass spectrometry applications. The company's technology enhances the efficiency of sample preparation, significantly increasing throughput while providing highly accurate and complex analytical results in a single step. This innovation addresses common challenges faced by researchers and industry professionals in sectors such as pharmaceuticals, food science, cosmetics, forensics, and government laboratories. By streamlining the analysis process and reducing the required sample volumes, SwissSource enables clients to effectively tackle complex sample screening, ultimately enhancing both research and operational productivity across various fields.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Prediva SA, founded in 2019 and based in Cottens, Switzerland, develops predictive machine learning software for the diagnosis and treatment of coronary artery disease. The company's innovative platform integrates medical image analysis with machine learning models and computational fluid dynamics simulations to create personalized 3D models of coronary arteries. This technology allows for the prediction of plaque progression and offers recommendations for stent placement and treatment planning. By equipping clinicians with insightful patient analyses, Prediva enables evidence-based treatment decisions that aim to reduce costs, procedure times, and the need for invasive interventions.

Readily3D is a Swiss company based in Lausanne, specializing in volumetric 3D printing solutions. Founded in 2020 as a spin-off from the École Polytechnique Fédérale de Lausanne (EPFL), the company has developed innovative printers capable of producing complex, patient-specific devices in under 30 seconds using tomography. Their technology utilizes a liquid photosensitive polymer, which is cured through dynamic light patterns from multiple angles, allowing for the creation of tailored orthoses for patients with hearing loss and surgical models for medical professionals. This approach not only enhances patient care but also streamlines surgical planning, positioning Readily3D as a leader in the advancement of personalized medical devices.

Hemolytics is a MedTech company focused on advancing malaria detection through the development of a medical diagnostic device. This innovative device utilizes a chemical amplification method to enhance the sensitivity of malaria detection, achieving a level ten times greater than existing malaria rapid diagnostic tests. By amplifying a pan-malarial biomarker with stable and inexpensive reagents, Hemolytics aims to provide a point of care test that allows for the early detection of malaria, ultimately improving patient outcomes and facilitating timely treatment.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

MOMM Diagnostics is a Swiss company founded in 2018 and headquartered in Basel. It specializes in the development of an in-vitro diagnostic test aimed at the early diagnosis of preeclampsia, a serious condition that can affect pregnant women. The company's innovative diagnostic device is designed for use at the point of care, allowing for quicker diagnosis and intervention, thereby improving patient outcomes. By focusing on women's health, MOMM Diagnostics aims to provide essential support to healthcare providers and enhance the care of pregnant women experiencing potential complications.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

Limula is a company that has developed an innovative platform technology designed to enhance the scalability of cell therapy production. By integrating a bioreactor and a centrifuge into a single device, Limula's solution enables healthcare providers to manufacture cell and gene therapies in a decentralized manner, bringing these treatments closer to patients. This platform, which includes hardware, software, and consumables, aims to make highly personalized and curative therapies more accessible. The automation of the production process not only increases safety and reproducibility but also allows for the large-scale manufacturing of cell therapy products, thereby addressing the critical need for improved access to gene-engineered therapies.

Touchless Automation GmbH is a high-tech company based in Biel/Bienne, Switzerland, specializing in the production of contactless handling equipment for the manipulation, assembly, and inspection of small components, particularly in the optoelectronic, MEMS, and micro-optical sectors. Founded in 2016, the company offers innovative solutions such as Levio, an automatic die sorter that efficiently picks up components from adhesive tapes, and Paradigma, a platform designed for pick and place operations without physical contact. Their technology is applicable across various industries, including aerospace, semiconductor, optoelectronics, luxury watches, microsystems, and medtech, facilitating processes such as inspection, sorting, palletizing, and assembly. Touchless Automation's systems enable the handling of components ranging from 0.1 to 20 millimeters, significantly enhancing production yield and operational efficiency.

Prediva SA, founded in 2019 and based in Cottens, Switzerland, develops predictive machine learning software for the diagnosis and treatment of coronary artery disease. The company's innovative platform integrates medical image analysis with machine learning models and computational fluid dynamics simulations to create personalized 3D models of coronary arteries. This technology allows for the prediction of plaque progression and offers recommendations for stent placement and treatment planning. By equipping clinicians with insightful patient analyses, Prediva enables evidence-based treatment decisions that aim to reduce costs, procedure times, and the need for invasive interventions.

Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

ONtrack Diagnostics is a medical technology company based in Zurich, Switzerland, that specializes in the development of non-invasive assays aimed at the screening, diagnosis, and monitoring of cancer. The company's initial product is a urine assay designed specifically for the screening of prostate cancer, reflecting its commitment to advancing cancer detection methods. Through its innovative approaches, ONtrack Diagnostics seeks to improve patient outcomes in the field of oncology.

CorasMedical is the development, production and sale of medical devices. It may set up branches and agencies at home and abroad, set up subsidiaries, participate in other ventures, acquire, manage and dispose of intellectual property and real estate, and enter into all business and contracts that directly or indirectly promote the purpose of the Company or which concern the investment and management of the Company's assets.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Rapid Graft develops a novel dermatome to easily take small split-skin grafts to improve treatment of chronic wound patients and to cover future needs in tissue engineering. Rapid Graft is headquartered in Zurich, Switzerland.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

Dicronis strive to enhance the quality-of-life of patients with their innovative technology. The first product in their pipeline, Lymphit, measures patient’s lymphatic function in a safe, home-based and highly scalable manner. The initial indication of Lymphit is the earliest possible diagnosis of secondary lymphedema, a serious side effect of many cancer therapies. By remotely monitoring the lymphatic function, the physician is enabled for the first time to perform an early diagnosis, before the swelling has occurred, and evaluate the best conservative treatment for the patient. This leads to a great improvement of the prognosis and quality of life of the patient and important savings for the healthcare system and society.

Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.

Flares Analytics provides a device which is able to detect early signs of the COPD.

Comphya is focused on developing an innovative implantable medical device aimed at restoring erectile function in patients who do not respond to oral medications for erectile dysfunction (ED). The company's device utilizes self-controlled stimulation through a wireless remote control that targets the cavernous nerve, thereby enabling patients to regain natural erectile function. This approach offers a safe and effective alternative for a significant segment of the male population experiencing ED, ultimately enhancing their quality of life.

Aesyra SA, founded in 2017 and based in Lausanne, Switzerland, specializes in the design and manufacture of medical devices focused on managing sleep disorders. The company's flagship product, AesyBite, is an intra-oral sensor that monitors and alleviates sleep bruxism, a condition characterized by teeth grinding during sleep. Aesyra's technology enables dental professionals to conduct intraoral measurements while patients sleep, allowing for the detection of bruxism and other sleep-related issues, such as obstructive sleep apnea. By providing accurate monitoring and biofeedback alternatives, Aesyra aims to help healthcare providers reduce damage to dental prostheses caused by occlusal problems and improve overall sleep quality for their patients.

Scewo AG, founded in 2017 and headquartered in Winterthur, Switzerland, specializes in designing and manufacturing innovative electric wheelchairs tailored for individuals with mobility impairments. The company has developed a unique stair-climbing wheelchair that integrates both wheels and tracks, allowing for enhanced maneuverability over various terrains, including curbs, tram tracks, grass, and uneven surfaces. This self-balancing wheelchair features an active control system that maintains stability and levelness, enabling users to navigate obstacles with ease. Users can control the chair through a joystick or by shifting their body weight, providing a versatile solution to improve mobility and independence for those with disabilities.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

Comphya is focused on developing an innovative implantable medical device aimed at restoring erectile function in patients who do not respond to oral medications for erectile dysfunction (ED). The company's device utilizes self-controlled stimulation through a wireless remote control that targets the cavernous nerve, thereby enabling patients to regain natural erectile function. This approach offers a safe and effective alternative for a significant segment of the male population experiencing ED, ultimately enhancing their quality of life.

Flares Analytics provides a device which is able to detect early signs of the COPD.

Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.

Dicronis strive to enhance the quality-of-life of patients with their innovative technology. The first product in their pipeline, Lymphit, measures patient’s lymphatic function in a safe, home-based and highly scalable manner. The initial indication of Lymphit is the earliest possible diagnosis of secondary lymphedema, a serious side effect of many cancer therapies. By remotely monitoring the lymphatic function, the physician is enabled for the first time to perform an early diagnosis, before the swelling has occurred, and evaluate the best conservative treatment for the patient. This leads to a great improvement of the prognosis and quality of life of the patient and important savings for the healthcare system and society.

ReflectUS develops a new diagnostic device for breast cancer diagnosis based on innovations in ultrasound imaging.

TWIICE is a Swiss company established in 2015 that specializes in the development and manufacturing of lower limb exoskeletons tailored for individuals with mobility impairments, particularly paraplegics. The exoskeletons are designed to assist users in standing and walking, incorporating electric motors that facilitate movement in the hip and knee joints. By offering customer-specific solutions that adapt to various morphologies and pathologies, TWIICE aims to restore the sensations and benefits associated with ambulation, thereby promoting greater independence in daily activities for individuals facing mobility challenges.

Ophthorobotics AG, founded in 2014 and based in Klosters, Switzerland, develops an innovative automated system for delivering intravitreal injections aimed at treating chronic ocular diseases. The company focuses on enhancing patient safety and comfort through advanced technology, including eye tracking and automated video documentation. Ophthorobotics is dedicated to creating the first fully automated injection system that ensures precise and safe procedures. This system is designed to operate within a sterile environment and includes necessary consumables, thereby improving the efficiency of treatment in hospitals. By streamlining the injection process, Ophthorobotics aims to reduce procedure times, minimize costs for medical staff, and enhance data storage and documentation, ultimately increasing the accessibility and safety of ophthalmic treatments.

SensArs is a medical equipment manufacturing company specializing in neuromodulation technology aimed at treating diabetic neuropathy. The company has developed an innovative implantable neurostimulator electrode designed to restore sensory feedback by delivering precise electrical impulses to the nerve fibers that transmit pain signals. This technology not only assists healthcare providers in enhancing patient functionality but also offers a long-term solution for pain management. SensArs' flagship system, SENSY, is particularly beneficial for patients with amputations or nerve damage, as it helps to restore natural sensations in their feet.

Sleepiz AG, based in Zurich, Switzerland, specializes in manufacturing a non-contact sleep monitoring device aimed at enhancing healthcare accessibility in home environments. Incorporated in 2018, the company's innovative product is designed to be placed on a bedside table, where it accurately measures patients' breathing patterns, heart rate, and body movements using advanced wireless millimeter wave technology and artificial intelligence. This device not only facilitates the diagnosis of sleep disorders but also enables long-term monitoring of chronic diseases, allowing healthcare providers to track patient progression and implement timely interventions for improved treatment outcomes. Through its user-friendly and precise approach, Sleepiz is positioned to significantly contribute to patient-centric disease management.

Dicronis strive to enhance the quality-of-life of patients with their innovative technology. The first product in their pipeline, Lymphit, measures patient’s lymphatic function in a safe, home-based and highly scalable manner. The initial indication of Lymphit is the earliest possible diagnosis of secondary lymphedema, a serious side effect of many cancer therapies. By remotely monitoring the lymphatic function, the physician is enabled for the first time to perform an early diagnosis, before the swelling has occurred, and evaluate the best conservative treatment for the patient. This leads to a great improvement of the prognosis and quality of life of the patient and important savings for the healthcare system and society.

Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

Ophthorobotics AG, founded in 2014 and based in Klosters, Switzerland, develops an innovative automated system for delivering intravitreal injections aimed at treating chronic ocular diseases. The company focuses on enhancing patient safety and comfort through advanced technology, including eye tracking and automated video documentation. Ophthorobotics is dedicated to creating the first fully automated injection system that ensures precise and safe procedures. This system is designed to operate within a sterile environment and includes necessary consumables, thereby improving the efficiency of treatment in hospitals. By streamlining the injection process, Ophthorobotics aims to reduce procedure times, minimize costs for medical staff, and enhance data storage and documentation, ultimately increasing the accessibility and safety of ophthalmic treatments.

Immunas develops a point-of-care diagnostic device that within minutes will be able to determine if the source of infection is bacterial or viral. This will lead to informed antibiotic treatment decisions and reduce the number of avoidable deaths in societies due to antimicrobial resistance. Immunas is a med-tech start-up aiming to develop a rapid test allowing doctors to accurately distinguish the sources of infection. The test reduces antibiotic overuse and helps minimize antibiotic resistance. Patients receive optimal treatment faster with the test. Unlike traditional procedures that take hours to days to complete, Immunas' cutting edge chip-based technology, within minutes, will be able to accurately determine whether the cause of infection is bacterial or viral. Together with cost-effectiveness, ease-of-use, minimal invasiveness for the patient and immense potential impact on pressing public health concerns, we genuinely hope to enable smart and responsible use of antibiotics for the benefits of patients and for societies at large.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

SensArs is a medical equipment manufacturing company specializing in neuromodulation technology aimed at treating diabetic neuropathy. The company has developed an innovative implantable neurostimulator electrode designed to restore sensory feedback by delivering precise electrical impulses to the nerve fibers that transmit pain signals. This technology not only assists healthcare providers in enhancing patient functionality but also offers a long-term solution for pain management. SensArs' flagship system, SENSY, is particularly beneficial for patients with amputations or nerve damage, as it helps to restore natural sensations in their feet.

SensArs is a medical equipment manufacturing company specializing in neuromodulation technology aimed at treating diabetic neuropathy. The company has developed an innovative implantable neurostimulator electrode designed to restore sensory feedback by delivering precise electrical impulses to the nerve fibers that transmit pain signals. This technology not only assists healthcare providers in enhancing patient functionality but also offers a long-term solution for pain management. SensArs' flagship system, SENSY, is particularly beneficial for patients with amputations or nerve damage, as it helps to restore natural sensations in their feet.

ImmuProbe develops a protein quantification system, which is characterized by both an outstanding performance at very small sample volumes as well as low acquisition and consumable costs. We designed an approach to outmatching state-of-the-art technology in terms of usability, speed, and customisability: the BoxProbe. With this system, we intend to overcome the current limitations in research studies relying on small laboratory animals, resulting in improved quality of obtained data and drastically decreasing the number of animals needed, allowing scientists to efficiently apply the principles of the three Rs (replace, refine, reduce) of animal welfare. In the long-term future, we will apply our technology to improve the present practice in infant diagnostics.

IRsweep AG, founded in 2014 and based in Zürich, Switzerland, specializes in the development and manufacture of advanced optical spectrometers, particularly for the mid-infrared region. The company’s flagship product, the IRis-F1, leverages Quantum Cascade Laser Frequency Combs, a technology developed by its co-founders at ETH Zurich in 2012. This innovative spectrometer is designed to achieve high measurement speeds, allowing for microsecond time resolution, which is crucial for observing rapid molecular processes such as protein folding and enzyme kinetics. IRsweep's products, including the compact IRcell, enhance the capabilities of spectroscopy by enabling users to analyze lower concentrations of substances more effectively. The technology is set to transform process analytics and may pave the way for portable applications in various industrial and laboratory settings.

Lambda Health System is a spin-off of the University of Applied Sciences of Canton de Vaud, focusing on development, production and commercialization of a rehabilitation robot for the lower limbs : LAMBDA. The LAMBDA is a cost-effective and easy to use robot which answers to the current needs of therapists. It offers various therapies usually contained in several devices with totally customizable parameters.

Ava is a company that focuses on enhancing women's health by providing tools for understanding their reproductive cycles and overall well-being. It offers a wearable medical device that includes a sensor bracelet paired with a mobile application and advanced backend technology. This system utilizes self-learning algorithms to monitor hormonal changes, accurately track ovulation, and identify potential health issues. By delivering reliable data related to fertility, pregnancy, and menopause, Ava empowers women to make informed decisions about their health and maximize their physical and emotional potential.

Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

Lucentix develops a biosensor technology that enables patients to measure concentrations of analytes in a single drop of blood or saliva by using a low-cost handheld device giving laboratory-quality results. The company's biosensors are based on the invention of a new type of biochemical sensing molecule. A light-producing enzyme called luciferase, is engineered to change the color of the emitted light in response to changes in analyte concentration. In absence of the analyte the molecular system emits red light, while at high analyte concentration the light is blue. Lucentix is headquartered in Lausanne, Switzerland.

Lambda Health System is a spin-off of the University of Applied Sciences of Canton de Vaud, focusing on development, production and commercialization of a rehabilitation robot for the lower limbs : LAMBDA. The LAMBDA is a cost-effective and easy to use robot which answers to the current needs of therapists. It offers various therapies usually contained in several devices with totally customizable parameters.

IRsweep AG, founded in 2014 and based in Zürich, Switzerland, specializes in the development and manufacture of advanced optical spectrometers, particularly for the mid-infrared region. The company’s flagship product, the IRis-F1, leverages Quantum Cascade Laser Frequency Combs, a technology developed by its co-founders at ETH Zurich in 2012. This innovative spectrometer is designed to achieve high measurement speeds, allowing for microsecond time resolution, which is crucial for observing rapid molecular processes such as protein folding and enzyme kinetics. IRsweep's products, including the compact IRcell, enhance the capabilities of spectroscopy by enabling users to analyze lower concentrations of substances more effectively. The technology is set to transform process analytics and may pave the way for portable applications in various industrial and laboratory settings.

Vibwife GmbH, founded in 2015 and located in Nidau, Switzerland, specializes in the development of an innovative mattress called Vibwife One, designed to assist women during labor. This product actively mobilizes the birthing woman by mimicking established manual mobilization techniques used by midwives. The aim of this mattress is to facilitate the birthing process, potentially shortening the duration of labor and reducing the likelihood of cesarean sections and other complications. By providing this supportive technology, Vibwife enhances the childbirth experience for both mothers and healthcare professionals.

Ava is a company that focuses on enhancing women's health by providing tools for understanding their reproductive cycles and overall well-being. It offers a wearable medical device that includes a sensor bracelet paired with a mobile application and advanced backend technology. This system utilizes self-learning algorithms to monitor hormonal changes, accurately track ovulation, and identify potential health issues. By delivering reliable data related to fertility, pregnancy, and menopause, Ava empowers women to make informed decisions about their health and maximize their physical and emotional potential.

Lucentix develops a biosensor technology that enables patients to measure concentrations of analytes in a single drop of blood or saliva by using a low-cost handheld device giving laboratory-quality results. The company's biosensors are based on the invention of a new type of biochemical sensing molecule. A light-producing enzyme called luciferase, is engineered to change the color of the emitted light in response to changes in analyte concentration. In absence of the analyte the molecular system emits red light, while at high analyte concentration the light is blue. Lucentix is headquartered in Lausanne, Switzerland.

IRsweep AG, founded in 2014 and based in Zürich, Switzerland, specializes in the development and manufacture of advanced optical spectrometers, particularly for the mid-infrared region. The company’s flagship product, the IRis-F1, leverages Quantum Cascade Laser Frequency Combs, a technology developed by its co-founders at ETH Zurich in 2012. This innovative spectrometer is designed to achieve high measurement speeds, allowing for microsecond time resolution, which is crucial for observing rapid molecular processes such as protein folding and enzyme kinetics. IRsweep's products, including the compact IRcell, enhance the capabilities of spectroscopy by enabling users to analyze lower concentrations of substances more effectively. The technology is set to transform process analytics and may pave the way for portable applications in various industrial and laboratory settings.

Ceveeo develops a wearable device that tracks and analyzes every step, movement, and different health indicators of animals especially dogs. This device comes with a sophisticated sensor and the accompanying app.

Ava is a company that focuses on enhancing women's health by providing tools for understanding their reproductive cycles and overall well-being. It offers a wearable medical device that includes a sensor bracelet paired with a mobile application and advanced backend technology. This system utilizes self-learning algorithms to monitor hormonal changes, accurately track ovulation, and identify potential health issues. By delivering reliable data related to fertility, pregnancy, and menopause, Ava empowers women to make informed decisions about their health and maximize their physical and emotional potential.

Xsensio is a digital health company focused on addressing the challenge of real-time, continuous monitoring of health parameters. It is developing an innovative Lab-on-Skin wearable device that serves as a miniaturized sensing platform, enabling continuous and real-time analysis of biochemical information at the skin's surface. This technology allows for the precise measurement of various health indicators, such as electrolytes, metabolites, hormones, and proteins, akin to traditional blood tests but in a minimally invasive manner. By providing unprecedented insights during critical health events, Xsensio aims to enhance patient care and shift the healthcare industry from a static to a dynamic approach in health monitoring.

Lucentix develops a biosensor technology that enables patients to measure concentrations of analytes in a single drop of blood or saliva by using a low-cost handheld device giving laboratory-quality results. The company's biosensors are based on the invention of a new type of biochemical sensing molecule. A light-producing enzyme called luciferase, is engineered to change the color of the emitted light in response to changes in analyte concentration. In absence of the analyte the molecular system emits red light, while at high analyte concentration the light is blue. Lucentix is headquartered in Lausanne, Switzerland.

Composyt Light Labs is a company focused on creating ultra-compact wearable display technology that seamlessly integrates with standard eyewear, paving the way for innovative smart glasses. As a spin-off from the Swiss Federal Institute of Technology in Lausanne, Switzerland, the company aims to enhance the eyewear market by offering not only aesthetic smart glasses but also computer display protection spectacles. These products are designed to assist individuals with vision issues, contributing to eye health while providing quality eye accessories.

Xsensio is a digital health company focused on addressing the challenge of real-time, continuous monitoring of health parameters. It is developing an innovative Lab-on-Skin wearable device that serves as a miniaturized sensing platform, enabling continuous and real-time analysis of biochemical information at the skin's surface. This technology allows for the precise measurement of various health indicators, such as electrolytes, metabolites, hormones, and proteins, akin to traditional blood tests but in a minimally invasive manner. By providing unprecedented insights during critical health events, Xsensio aims to enhance patient care and shift the healthcare industry from a static to a dynamic approach in health monitoring.